Lipum AB (publ)

OM:LIPUM Stock Report

Market Cap: SEK 319.2m

Lipum Valuation

Is LIPUM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LIPUM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LIPUM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LIPUM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LIPUM?

Key metric: As LIPUM is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for LIPUM. This is calculated by dividing LIPUM's market cap by their current book value.
What is LIPUM's PB Ratio?
PB Ratio106.9x
BookSEK 2.99m
Market CapSEK 319.25m

Price to Book Ratio vs Peers

How does LIPUM's PB Ratio compare to its peers?

The above table shows the PB ratio for LIPUM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.2x
XBRANE Xbrane Biopharma
2.1x56.77%SEK 447.1m
ISOFOL Isofol Medical
3.4xn/aSEK 262.6m
INIT Initiator Pharma
19.1x-21.24%SEK 338.1m
IMMU Mendus
0.4x28.14%SEK 262.9m
LIPUM Lipum
106.9x80.96%SEK 319.2m

Price-To-Book vs Peers: LIPUM is expensive based on its Price-To-Book Ratio (106.9x) compared to the peer average (6.2x).

Price to Book Ratio vs Industry

How does LIPUM's PB Ratio compare vs other companies in the SE Biotechs Industry?

7 CompaniesPrice / BookEstimated GrowthMarket Cap
IMMU Mendus
0.4x28.14%US$26.78m
PROGEN Prostatype Genomics
0.3xn/aUS$1.18m
SPERM Spermosens
0.3xn/aUS$1.13m
APTA Aptahem
0.2xn/aUS$1.02m
LIPUM 106.9xIndustry Avg. 2.7xNo. of Companies10PB0246810+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: LIPUM is expensive based on its Price-To-Book Ratio (106.9x) compared to the Swedish Biotechs industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is LIPUM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LIPUM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio106.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LIPUM's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystConsensusTarget
Consensus Narrative from 1 Analyst
SEK 24.00
Fair Value
37.3% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 11:23
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lipum AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kevin SuleRedeye